Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Bristol Myers Squibb Company BMY

Healthcare — Drug Manufacturers General
S&P 500 Member Dividend Champion (3y)
Indexes indicate stock being part of an index ,
Growth Flags show if company had growth for consecutive years

Bristol Myers Squibb Company (BMY) Business Profile

Company Overview

Bristol Myers Squibb Company (BMY) is a leading global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. The company was founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, New York. Over the years, BMY has grown through strategic mergers and acquisitions, including its landmark acquisition of Celgene in 2019, which significantly expanded its oncology and immunology portfolio. Headquartered in New York City, BMY operates in over 60 countries worldwide.

The company is led by Giovanni Caforio, M.D., who serves as Chairman and Chief Executive Officer. Under his leadership, BMY has focused on advancing its pipeline of innovative therapies, expanding its global reach, and driving sustainable growth. The executive team includes key leaders such as David Elkins (Chief Financial Officer) and Rupert Vessey (President of Research and Early Development), who play pivotal roles in shaping the company’s strategic direction.

Core Business Segments

Bristol Myers Squibb operates across several core business segments, focusing on therapeutic areas with high unmet medical needs. These segments include:

1. Oncology

BMY is a leader in oncology, offering a robust portfolio of therapies aimed at treating various types of cancer. Key products in this segment include:

  • Opdivo (nivolumab): A leading immunotherapy used to treat multiple cancers, including lung, melanoma, and renal cell carcinoma.
  • Yervoy (ipilimumab): Often used in combination with Opdivo, it is a monoclonal antibody for treating melanoma and other cancers.
  • Revlimid (lenalidomide): Acquired through the Celgene acquisition, it is a cornerstone therapy for multiple myeloma and other hematologic malignancies.
  • Abraxane (paclitaxel protein-bound): A chemotherapy drug used to treat breast, lung, and pancreatic cancers.

2. Immunology and Inflammation

BMY develops therapies to address autoimmune and inflammatory diseases. Key products include:

  • Orencia (abatacept): A biologic therapy for rheumatoid arthritis and other autoimmune conditions.
  • Zeposia (ozanimod): A treatment for multiple sclerosis and ulcerative colitis.

3. Cardiovascular

BMY has a strong presence in cardiovascular medicine, focusing on conditions such as atrial fibrillation and heart failure. Key products include:

  • Eliquis (apixaban): A leading anticoagulant used to reduce the risk of stroke and blood clots in patients with atrial fibrillation.

4. Hematology

This segment focuses on blood disorders and includes therapies like:

  • Reblozyl (luspatercept-aamt): A treatment for anemia in patients with beta-thalassemia and myelodysplastic syndromes.

5. Cell Therapy

BMY is at the forefront of cell therapy, leveraging cutting-edge technology to develop personalized treatments. Key products include:

  • Breyanzi (lisocabtagene maraleucel): A CAR T-cell therapy for large B-cell lymphoma.
  • Abecma (idecabtagene vicleucel): A CAR T-cell therapy for multiple myeloma.

Business Model

Bristol Myers Squibb’s business model is centered on innovation, strategic partnerships, and a focus on high-growth therapeutic areas. The company invests heavily in research and development (R&D), allocating approximately 25% of its annual revenue to advancing its pipeline of therapies. BMY generates revenue primarily through the sale of prescription medicines, with a significant portion coming from its blockbuster drugs like Opdivo, Eliquis, and Revlimid.

The company also collaborates with academic institutions, biotech firms, and other pharmaceutical companies to accelerate drug discovery and development. Licensing agreements and co-development partnerships further enhance its ability to bring innovative therapies to market.

Strategic Direction

BMY’s strategic priorities include:

  • Pipeline Expansion: The company is focused on advancing its late-stage pipeline, particularly in oncology, immunology, and cardiovascular medicine. Promising candidates include relatlimab (a LAG-3 inhibitor) and deucravacitinib (a TYK2 inhibitor).
  • Global Reach: BMY aims to expand its presence in emerging markets, leveraging its diverse portfolio to address unmet medical needs worldwide.
  • Sustainability Goals: The company is committed to reducing its environmental footprint, with targets to achieve carbon neutrality by 2040 and reduce water usage and waste.
  • Digital Transformation: BMY is investing in digital technologies to enhance drug discovery, improve patient outcomes, and streamline operations.

Competitive Landscape

Bristol Myers Squibb operates in a highly competitive industry, facing competition from both large pharmaceutical companies and smaller biotech firms. Key competitors include:

  • Pfizer: Competes in oncology and cardiovascular medicine, particularly with its anticoagulant Xarelto.
  • Merck & Co.: A major competitor in immuno-oncology with its blockbuster drug Keytruda.
  • Roche: Known for its strong oncology portfolio, including drugs like Avastin and Herceptin.
  • Novartis: Competes in oncology, immunology, and cell therapy.
  • Amgen: A leader in biologics and biosimilars, competing in oncology and immunology.

Risk Factors

BMY faces several risks that could impact its business operations and financial performance:

  • Patent Expirations: The loss of exclusivity for key drugs like Revlimid and Eliquis could lead to revenue declines.
  • Regulatory Challenges: The pharmaceutical industry is heavily regulated, and delays or rejections in drug approvals can impact growth.
  • Market Dependence: A significant portion of revenue comes from a few blockbuster drugs, making the company vulnerable to market shifts.
  • Supply Chain Disruptions: Global supply chain issues, including raw material shortages, could affect production and distribution.
  • Competition: Intense competition from generics and biosimilars poses a threat to market share.

Recent Developments

  • FDA Approvals: In 2023, BMY received FDA approval for Camzyos (mavacamten), a first-in-class treatment for obstructive hypertrophic cardiomyopathy.
  • Acquisitions: The company acquired MyoKardia in 2020 to strengthen its cardiovascular portfolio.
  • COVID-19 Impact: While the pandemic disrupted clinical trials and supply chains, BMY adapted by leveraging digital tools and remote monitoring.
  • Sustainability Initiatives: BMY launched its “Environmental, Social, and Governance (ESG) Strategy” to address climate change and promote diversity and inclusion.

Investment Considerations

Strengths:

  • Strong portfolio of blockbuster drugs.
  • Robust pipeline with promising late-stage candidates.
  • Global presence and market leadership in oncology and cardiovascular medicine.
  • Commitment to innovation and sustainability.

Risks:

  • Dependence on a few key products for revenue.
  • Patent expirations and competition from generics.
  • Regulatory and geopolitical risks.

Conclusion

Bristol Myers Squibb is a global leader in biopharmaceutical innovation, with a strong focus on oncology, immunology, and cardiovascular medicine. The company’s commitment to R&D, strategic acquisitions, and sustainability positions it well for future growth. However, investors should consider the risks associated with patent expirations and market competition. Overall, BMY remains a compelling player in the pharmaceutical industry, poised to address unmet medical needs and deliver long-term value.

© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us